Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: U.S./EU device MRA

This article was originally published in The Gray Sheet

Executive Summary

U.S./EU device MRA: April 25 teleconference between U.S. and European Union negotiators on a medical device mutual recognition agreement outlines remaining work to be done but produces no substantial headway on key issues of product coverage and identification of notified bodies, FDA staffers say. The next teleconference is set for May 5, with agency seeking possible face-to-face meetings in Washington or Brussels during the weeks of May 12 or May 19. An April 19 letter from EU President Jaques Santer to President Clinton places additional pressure to complete negotiations before a May 28 Summit meeting in The Hague, The Netherlands. That correspondence urges Clinton to take "personal intervention" in the MRA negotiations and notes that in medical devices and drugs, "the product coverage proposed by the U.S. side is far too limited and the commitment to recognize the results of our assessments too lose"...

You may also be interested in...



Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

UsernamePublicRestriction

Register

MT007967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel